ClinVar Miner

Submissions for variant NM_002437.5(MPV17):c.408+1G>A

gnomAD frequency: 0.00001  dbSNP: rs749361266
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000479349 SCV000574046 likely pathogenic not provided 2018-09-20 criteria provided, single submitter clinical testing The c.408+1G>A variant in the MPV17 gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This splice site variant destroys the canonical splice donor site in intron 6. It is predicted to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. The c.408+1G>A variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). We interpret c.408+1G>A as a likely pathogenic variant.
Fulgent Genetics, Fulgent Genetics RCV000763082 SCV000893606 likely pathogenic Mitochondrial DNA depletion syndrome 6 (hepatocerebral type) 2018-10-31 criteria provided, single submitter clinical testing
Invitae RCV000479349 SCV001576768 likely pathogenic not provided 2024-01-29 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 6 of the MPV17 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MPV17 are known to be pathogenic (PMID: 23714749). This variant is present in population databases (rs749361266, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with MPV17-related conditions. ClinVar contains an entry for this variant (Variation ID: 424255). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Natera, Inc. RCV000763082 SCV001462523 likely pathogenic Mitochondrial DNA depletion syndrome 6 (hepatocerebral type) 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.